Health
First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC – News-Medical.Net
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprisin…
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al. which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation.
The Oncota…
-
Noosa News21 hours agoNew South Wales Blues left to pick up the pieces after fumbling a chance at State of Origin glory
-
Noosa News15 hours agoHelp to make recycling stick
-
Noosa News13 hours agoFormer Darling Downs Zoo employee sheds new light on horrific lion attack on teacher Joanne Cabban
-
General21 hours agoAmidst grief and sadness, Cameron Munster plays another iconic State of Origin performance after his father’s death